CST BLOG

The official blog of Cell Signaling Technology, where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Amrik Singh, PhD

Amrik Singh, PhD

Amrik Singh is an Immunology Fellow at Cell Signaling Technology. He is a biochemist trained at Boston University Medical Center and Beth Israel Deaconess Medical Center. At CST, he is helping to develop and manage the adoptive cell therapy product portfolio with a specific interest in developing antibodies and assays to characterize CAR-T cells.

Recent Posts:

Immunology: What are lymphoid cells and how are they identified?

In humans, hematopoietic stem cells (HSCs) continuously replenish all types of blood cells via a ser...
Amrik Singh, PhDMay 21, 2025

Spatial Insights for CAR-Engineered Cells in Solid Tumors: Antibody-Based CAR Detection Method

Cell Signaling Technology provides products and services are for research use only and not for use i...
Amrik Singh, PhDApr 16, 2025

CAR T Cell Detection: Anti-CAR Linker Antibodies for Whitlow/218 & G4S

CST anti-CAR linker antibodies won The Innovation Award from CiteAb in 2023. Read on to learn why! —...
Amrik Singh, PhDNov 8, 2022

Targeting B-Cell Maturation Antigen (BCMA) Holds Promise for Multiple Myeloma Treatment

Multiple myeloma (MM) is a type of hematopoietic malignancy characterized, in part, by bone pain, an...
Amrik Singh, PhDAug 8, 2018

GPNMB: A Promising Immunotherapeutic Target for Triple Negative Breast Cancer

The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments tha...
Amrik Singh, PhDApr 4, 2018

    Recent Posts